EMEA-000731-PIP01-09-M03

Table of contents

Key facts

Invented name
Refixia
Active substance
Nonacog beta pegol
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0139/2019
PIP number
EMEA-000731-PIP01-09-M03
Pharmaceutical form(s)
Powder and solvent for solution for injection
Condition(s) / indication(s)
Treatment of hereditary factor IX deficiency
Route(s) of administration
Intravenous use
Contact for public enquiries
Novo Nordisk A/S

E-mail: paediatrics@novonordisk.com
Tel. +45 4444 8888

Decision type
PM: decision on the application for modification of an agreed PIP
Compliance procedure number
EMEA-C-000731-PIP01-09-M03
Compliance opinion date
15/11/2019
Compliance outcome
positive

Decision

Related content

How useful was this page?

Add your rating